Phase Ii Study Of Pembrolizumab Plus Gvd As Second-Line Therapy For Relapsed Or Refractory Classical Hodgkin Lymphoma

The international phase 2 CAPTIVATE (PCYC-1142) study evaluated ibrutinib (420 mg daily) plus venetoclax (ramped up to 400 mg daily) as first-line therapy in patients with CLL (Abstract 123). After 12 cycles of treatment, patients with confirmed undetectable MRD were randomly assigned in a double-blind manner to receive ibrutinib or placebo, and those with detectable MRD or unconfirmed undetectable MRD were randomly assigned to receive open-label ibrutinib monotherapy or ibrutinib plus venetoclax. The median age of the 164 patients was 58 years (range, 28-69), and the majority had at least 1 high-risk genetic feature. Among the patients with confirmed undetectable MRD before randomization, the rate of disease-free survival at 1 year after randomization was 100.0% in the ibrutinib group vs 95.3% in the placebo group (P=.1475). Across all 4 randomized cohorts, the 30-month PFS was between 95% and 100%. No new safety signals arose.